{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T18:02:51Z","timestamp":1776448971784,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.ejca.2012.06.003","type":"journal-article","created":{"date-parts":[[2012,7,6]],"date-time":"2012-07-06T00:45:56Z","timestamp":1341535556000},"page":"3223-3231","source":"Crossref","is-referenced-by-count":101,"title":["Bortezomib in combination with CHOP as first-line treatment for patients with stage III\/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial"],"prefix":"10.1016","volume":"48","clinical-trial-number":[{"clinical-trial-number":"nct00374699","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Seok Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hyeh","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jooryung","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Ick","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Kee","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Gu","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheolwon","family":"Suh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejca.2012.06.003_b0005","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejca.2012.06.003_b0010","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/cncr.20531","article-title":"Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi","volume":"101","author":"Morabito","year":"2004","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2012.06.003_b0015","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1016\/j.ejca.2012.06.003_b0020","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2012.06.003_b0025","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/annonc\/mdn431","article-title":"Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK\/T-cell lymphoma","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2012.06.003_b0030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ijc.21805","article-title":"Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin\u2019s lymphoma","volume":"119","author":"Leonard","year":"2006","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2012.06.003_b0035","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1158\/0008-5472.CAN-05-0676","article-title":"Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells","volume":"65","author":"Qin","year":"2005","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.ejca.2012.06.003_b0040","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/jnci\/djj334","article-title":"Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model","volume":"98","author":"Ishii","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.ejca.2012.06.003_b0045","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.onc.1204168","article-title":"Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin","volume":"20","author":"Arlt","year":"2001","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.ejca.2012.06.003_b0050","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1158\/1078-0432.CCR-03-0366","article-title":"Enhanced chemosensitivity to irinotecan by RNA interference-mediated down-regulation of the nuclear factor-kappaB p65 subunit","volume":"10","author":"Guo","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ejca.2012.06.003_b0055","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2012.06.003_b0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2007-02-072900","article-title":"Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)-cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation","volume":"110","author":"Shen","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejca.2012.06.003_b0065","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/ijc.25873","article-title":"Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of epstein-barr virus infection","volume":"129","author":"Iwata","year":"2011","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2012.06.003_b0070","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1349-7006.2008.01038.x","article-title":"Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1","volume":"100","author":"Ri","year":"2009","journal-title":"Cancer Sci"},{"issue":"27","key":"10.1016\/j.ejca.2012.06.003_b0075","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2012.06.003_b0080","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2012.06.003_b0085","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"17","key":"10.1016\/j.ejca.2012.06.003_b0090","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1200\/JCO.2004.10.087","article-title":"Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas","volume":"22","author":"Kuo","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2012.06.003_b0095","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/jjco\/hyp037","article-title":"NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK\/T-cell lymphoma, nasal type","volume":"39","author":"Liu","year":"2009","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2012.06.003_b0100","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1158\/1078-0432.CCR-04-1282","article-title":"Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer","volume":"11","author":"Lee","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2012.06.003_b0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1023\/A:1011144911781","article-title":"CHOP followed by involved field radiation: is it optimal for localized nasal natural killer\/T-cell lymphoma?","volume":"12","author":"Kim","year":"2001","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2012.06.003_b0110","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.V89.8.2966","article-title":"CD3\u2212 CD56+ non-Hodgkin\u2019s lymphomas with an aggressive behavior related to multidrug resistance","volume":"89","author":"Drenou","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ejca.2012.06.003_b0115","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2012.06.003_b0120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00277-008-0544-2","article-title":"Clinical features and prognostic factors of patients with \u201cperipheral T cell lymphoma, unspecified\u201d","volume":"88","author":"Lee","year":"2009","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.ejca.2012.06.003_b0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification","volume":"9","author":"Lopez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2012.06.003_b0130","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.2006.06124.x","article-title":"Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study","volume":"134","author":"Sung","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejca.2012.06.003_b0135","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.ejca.2012.06.003_b0140","doi-asserted-by":"crossref","first-page":"8554A","DOI":"10.1200\/jco.2009.27.15_suppl.8554","article-title":"A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1T trial","volume":"27","author":"Delmer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2012.06.003_b0145","doi-asserted-by":"crossref","first-page":"1011A","DOI":"10.1182\/blood.V110.11.3449.3449","article-title":"Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-Cell lymphomas (PTCL), the CONCEPT trial","volume":"110","author":"Foss","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejca.2012.06.003_b0150","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2012.06.003_b0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"10.1016\/j.ejca.2012.06.003_b0160","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-2559.2009.03263.x","article-title":"Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment","volume":"54","author":"Wondergem","year":"2009","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.ejca.2012.06.003_b0165","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3349\/ymj.2010.51.3.448","article-title":"Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient","volume":"51","author":"Kang","year":"2010","journal-title":"Yonsei Med J"},{"issue":"3","key":"10.1016\/j.ejca.2012.06.003_b0170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.5045\/kjh.2010.45.3.188","article-title":"The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma","volume":"45","author":"Yi","year":"2010","journal-title":"Korean J Hematol"},{"issue":"3","key":"10.1016\/j.ejca.2012.06.003_b0175","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jjco\/hyq194","article-title":"Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study","volume":"41","author":"Kim","year":"2011","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2012.06.003_b0180","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2012.06.003_b0185","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200473X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980491200473X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T09:37:29Z","timestamp":1642671449000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491200473X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":37,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S095980491200473X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.06.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}